elbasvir

Also known as mk-8742, carbamic acid, n,n'-(((6s)-6-phenyl-6h-indolo(1,2-c)(1,3)benzoxazine-3,10-diyl)bis(1h-imidazole-5,2-diyl-(2s)-2,1-pyrrolidinediyl((1s)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, c,c'-dimethyl ester, elbasvir component of zepatier, zepatier component of elbasvir

Elbasvir is a drug approved by the FDA in January 2016 for the treatment of hepatitis C. It was developed by Merck and completed Phase III trials, used in combination with the NS3/4A protease inhibitor grazoprevir under the trade name Zepatier, either with or without ribavirin.

Chemical data

Formula: C49H55N9O7
Molecular weight: 882 g/mol
IUPAC name: methyl N-[(2S)-1-[(2S)-2-[5-[(6S)-3-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazin-10-yl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate

via PubChem

Article

6 sections

Contents

Side effects
Interactions
Pharmacology
Mechanism of action
Pharmacokinetics
References

{{Drugbox | IUPAC_name = Dimethyl N,N’-([(6S)-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis{1H-imidazole-5,2-diyl-(2S)-pyrrolidine-2,1-diyl[(2S)-1-oxo-3-methylbutane-1,2-diyl]})biscarbamate | image = File:Elbasvir.svg | image_class = skin-invert-image | width = 350